Skip to main content
. 2022 Jun 29;14(7):1381. doi: 10.3390/pharmaceutics14071381

Figure 4.

Figure 4

PD-1/PD-L1-blocking activity of anti-EGFR/PD-L1 BsAbs was determined by PD-1/PD-L1 blockade cell-based assay (Promega) to assess the ability of the anti-EGFR/PD-L1 BsAbs to block PD-1/PD-L1 engagement compared to parental mAbs. This experiment has been performed in biological triplicates, and data are representative of two or more independent experiments.